SYS-CON MEDIA Authors: Jason Bloomberg, Eric Brown, Bob Gourley, Sandi Mappic, RealWire News Distribution

News Feed Item

ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th

LOS ANGELES, March 3, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA.  

ImmunoCellular Therapeutics Logo.

To access the live audio webcast of the ROTH presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.348.0010
[email protected]

Photo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

SOURCE ImmunoCellular Therapeutics, Ltd.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.